Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database

Béné, Johana; Moulis, Guillaume; Bennani, Ismail; Auffret, Marine; Coupé, Patrick; Babai, Samy; Hillaire‐Buys, Dominique; Micallef, Joëlle; Gautier, Sophie

doi:10.1111/bjd.14601

Cited by 158 publications

(134 citation statements)

References 34 publications

Supporting

Mentioning

121

Contrasting

Order By: Relevance

“…peptide 1 receptor agonists [GLP-1 RAs], sodium-glucose cotransporter 2 inhibitors [SGLT2is], thiazolidines, and any kind of insulins), other drugs that are reported as causal reagents for BP, and negative controls (2,5). An ROR is considered significant when the lower bound of the two-sided 95% CI for the risk of pemphigoid was larger than 1.…”

mentioning

confidence: 99%

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

et al. 2018

View full text Add to dashboard Cite

mentioning

confidence: 99%

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

et al. 2018

View full text Add to dashboard Cite

“…In France, there has been an average of 10 cases of possible DPP4i-induced BP cases per year from 2008 to 2012 [12,13].…”

mentioning

confidence: 99%

Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid

Schaffer¹,

Buclin

Jornayvaz³

et al. 2017

Dermatology

View full text Add to dashboard Cite

“…In this study, many cases with BP showed improvement approximately 10 days after discontinuation of p.o. administration of DPP‐4 inhibitor . Meanwhile, there have also been cases in which the condition is resolved several months after termination of treatment.…”

Section: Overview Of Pemphigoid Diseasesmentioning

confidence: 99%

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Ujiie

Iwata

Yamagami

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.

show abstract

Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database

Abstract: These data confirm a strong signal for an increased risk of bullous pemphigoid during DPP-IV inhibitor exposure. This adverse drug reaction is observed for each DPP-IV inhibitor, suggesting a class effect. The signal was higher with vildagliptin than with the other DPP-IV inhibitors.

Cited by 158 publications

References 34 publications

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Contact Info

Product

Resources

About